

Table S1. Additional characteristics of patients treated with MOV in the Czech Republic, January 1, 2022 – April 30, 2022 (N=621)

Patient characteristics	N=621
BMI (kg/m²)	
N used	621
Median (Min; Max)	28.70 (15.9; 65.8)
IQR	25.40; 33.60
Mean (SD)	30.18 (7.086)
Type of test used for COVID-19 diagnosis	
RT-PCR	489 (78.7%)
Antigen test	132 (21.3%)
COVID-19 variant	
Omicron (All BA. 1 and 2)	84 (13.5%)
Delta	5 (0.8%)
Unknown	532 (85.7%)
Time from last vaccination to baseline positive test (months)	
N used	500
Median (Min; Max)	3.68 (0.2; 12.7)
IQR	2.53; 4.83
Mean (SD)	4.05 (2.268)
Missing	32
Type of vaccination	
Comirnaty (Pfizer/BioNTech), Spikevax (Moderna), Vaxzevria (AstraZeneca), Jcovden (Janssen Pharmaceutica), Other or mixed vaccine application Unknown	361 (67.9%) 69 (13.0%) 21 (3.9%) 9 (1.7%) 52 (9.8%) 20 (3.8%)
Type and number of vaccinations	
Comirnaty (Pfizer/BioNTech)	N = 361
1	5 (1.4%)
2	68 (18.8%)
3	288 (79.8%)
Spikevax (Moderna),	N = 69
1	1 (1.4%)
2	11 (15.9%)
3	57 (82.6%)
Vaxzevria (AstraZeneca),	N = 21
1	1 (4.8%)
2	20 (95.2%)
Jcovden (Janssen Pharmaceutica)	N = 9

1	9 (100.0%)
---	------------

Table S2. Prevalence of additional comorbidities among patients treated with MOV in the Czech Republic, January 1, 2022 – April 30, 2022 (N=621)

Comorbidities	N=621
Heart conditions	92 (14.8%)
Cancer	91 (14.7%)
Asthma	78 (12.6%)
Chronic lung diseases	68 (11.0%)
Chronic liver disease	60 (9.7%)
Neurological conditions including dementia	59 (9.5%)
Chronic kidney disease	57 (9.2%)
Mental health disorders	42 (6.8%)
Cerebrovascular disease	28 (4.5%)
Primary thrombophilia	24 (3.9%)
Substance use	16 (2.6%)
Obstructive and central sleep apnea	14 (2.3%)
Immune deficiencies	8 (1.3%)
Solid organ or blood stem cell transplantation	6 (1.0%)
History of recurrent thromboembolic events	2 (0.3%)
Sickle cell disease	0
Beta Thalassemia	0
Tuberculosis	0
HIV	0
Number of comorbidities	
0	36 (5.8%)
1	142 (22.9%)
2	184 (29.6%)
3	125 (20.1%)
4	71 (11.4%)
≥ 5	63 (10.1%)

Table S3. Additional concomitant medications with a contraindication to or potential for major drug-drug interactions with nirmatrelvir/ritonavir among patients treated with MOV in the Czech Republic, January 1, 2022 – April 30, 2022 (N=621)

Concomitant medications	N=621
Neuropsychiatric drugs	93 (15.0%)
Inhaled and oral corticosteroids	67 (10.8%)
Oral anticoagulants	61 (9.8%)
Corticosteroids and other immunosuppressive meds	42 (6.8%)
Antibiotics	34 (5.5%)

Antiarrhythmic agents	32 (5.2%)
Antineoplastics	19 (3.1%)
Immunosuppressants	17 (2.7%)
Anticonvulsants	9 (1.4%)
Number of different concomitant medications	
0	83 (13.4%)
1	84 (13.5%)
2	103 (16.6%)
3	118 (19.0%)
4	77 (12.4%)
≥ 5	156 (25.1%)